Foghorn Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Foghorn TherapeuticsDer Gewinn des Unternehmens wird voraussichtlich um 2.8% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 32.1% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich um 5.9% pro Jahr wachsen.

Wichtige Informationen

-2.8%

Wachstumsrate der Gewinne

5.9%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	32.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	05 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 07

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target

May 09

Recent updates

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 07

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk

Oct 22

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Climb 35% But Its Business Is Yet to Catch Up

Sep 01

Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 27% But Growth Is Lacking

Jul 17

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target

May 09

Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth

Apr 12

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too

Feb 22

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth

Dec 13

Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues

Nov 07

Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans

Jun 14

Foghorn Therapeutics: Selling For Less Than Cash Value

Oct 10

Foghorn stock slumps 18% as FDA places full clinical hold on blood cancer trial of FHD-286

Aug 23

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:FHTX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	38	-110	-110	-84	6
12/31/2025	34	-91	-89	-90	8
12/31/2024	27	-91	-95	-100	6
9/30/2024	26	-91	-104	-103	N/A
6/30/2024	35	-86	-110	-110	N/A
3/31/2024	34	-93	-117	-116	N/A
12/31/2023	34	-98	-119	-118	N/A
9/30/2023	33	-103	-121	-119	N/A
6/30/2023	22	-115	-114	-112	N/A
3/31/2023	21	-112	-111	-109	N/A
12/31/2022	19	-109	192	194	N/A
9/30/2022	16	-109	233	234	N/A
6/30/2022	9	-109	233	234	N/A
3/31/2022	5	-105	243	244	N/A
12/31/2021	1	-101	-54	-50	N/A
9/30/2021	1	-93	-84	-73	N/A
6/30/2021	1	-85	-65	-50	N/A
3/31/2021	1	-78	-61	-44	N/A
12/31/2020	0	-69	-47	-31	N/A
9/30/2020	0	-63	-43	-34	N/A
6/30/2020	N/A	-58	-52	-49	N/A
3/31/2020	N/A	-54	-48	-47	N/A
12/31/2019	N/A	-51	-47	-46	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: FHTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: FHTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: FHTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: FHTXDie Einnahmen des Unternehmens (32.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: FHTXDie Einnahmen des Unternehmens (32.1% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von FHTX in 3 Jahren voraussichtlich hoch sein wird

Foghorn Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Consensus revenue estimates decrease by 33%, EPS upgraded

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target

Price target decreased by 18% to US$11.67

Consensus revenue estimates fall by 13%

Price target decreased by 9.8% to US$13.75

Recent updates

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk

Foghorn Therapeutics Inc. Announces First Patient Dosed with First-In-Class Oral Smarca2 Selective Inhibitor Fhd-909 in A Phase 1 Trial for Smarca4 Mutated Solid Tumors

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Climb 35% But Its Business Is Yet to Catch Up

Foghorn Therapeutics Inc. Announces Impairment of Long-Lived Assets for the Three Months Ended June 30, 2024

Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 27% But Growth Is Lacking

New minor risk - Shareholder dilution

Foghorn Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $109.999998 million.

Consensus revenue estimates decrease by 33%, EPS upgraded

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target

Price target decreased by 18% to US$11.67

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Foghorn Therapeutics Inc., Annual General Meeting, Jun 26, 2024

Foghorn Therapeutics Inc. Appoints Kristian Humer as Chief Financial Officer

Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth

Insider recently sold US$72k worth of stock

Consensus revenue estimates fall by 13%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Foghorn Therapeutics Inc. to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, Including the Selective Inhibitor of BRM, FHD-909

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too

New major risk - Share price stability

Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor

Foghorn Therapeutics Inc. Appoints Stephen J. Dipalma Interim Chief Financial Officer, Effective January 16, 2024

Foghorn Therapeutics Inc. Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024

Foghorn Therapeutics Inc. Announces Resignation of Allan Reine as Chief Financial Officer, Effective January 16, 2024

Price target decreased by 9.8% to US$13.75

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth

Consensus revenue estimates increase by 48%

Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Foghorn Therapeutics Inc. to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

Foghorn Therapeutics Inc. Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed And/Or Refractory AML

Chief Medical Officer notifies of intention to sell stock

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans

Foghorn Therapeutics Announces FDA Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients

Price target decreased by 10% to US$16.33

Consensus EPS estimates upgraded to US$2.60 loss

Consensus revenue estimates fall by 28%

Price target decreased by 7.9% to US$19.80

Full year 2022 earnings: EPS and revenues miss analyst expectations

Foghorn Therapeutics Inc. Announces New Preclinical Data for FHD-286 in AML to Be Presented At the American Society of Hematology Annual Meeting

Price target decreased to US$21.50

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Foghorn Therapeutics Inc. Appoints Thomas J. Lynch to Its Board of Directors

Foghorn Therapeutics Announces New Data Demonstrating Brd9 Degradation in Patient Tumor Biopsies and Discloses New Selective Cbp Program

Foghorn Therapeutics: Selling For Less Than Cash Value

Press Release: Foghorn Therapeutics Announces Resignation of Cigall Kadoch from Board, Effective August 31, 2022

Price target decreased to US$21.50

Foghorn Therapeutics Inc. Provides Further Update on FHD-286 Phase I Study in Relapsed/Refractory AML/MDS

Foghorn stock slumps 18% as FDA places full clinical hold on blood cancer trial of FHD-286

Foghorn Therapeutics Inc. Appoints Lynne Parshall to Its Board of Directors

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Foghorn Therapeutics GAAP EPS of -$0.66 misses by $0.07, revenue of $4.49M

Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from Russell Microcap Value Index

Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity

Price target decreased to US$26.25

Foghorn Therapeutics Inc. Provides Update on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML and MDS

Consensus revenue estimates fall by 27%

Foghorn Therapeutics Inc., Annual General Meeting, Jun 21, 2022

Price target increased to US$28.25

We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Chief Scientific Officer exercised options to buy US$1.8m worth of stock.

Price target increased to US$27.50

Foghorn Therapeutics Inc. Announces First Patient Dosed in First-In-Human Clinical Trial of FHD-609

Consensus forecasts updated